Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.32 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urea SCHEMBL4909809 | 0.95 | PSMB8 (0.34) | PSMB8PSMB5EGLN1KDM6BKDM5C | |
| SCHEMBL43575 | 0.94 | EGLN1 (0.36) | PSMB8PSMB5EGLN1KDM6BKDM5C | |
| Thioglycolic Acid SCHEMBL27511458 | 0.94 | PSMB8 (0.33) | PSMB8PSMB5EGLN1KDM6BKDM5C | |
| Ethylene Glycol SCHEMBL999673 | 0.93 | PSMB8 (0.36) | PSMB8PSMB5LMNAMGLL | |
| Di(Hydroxyethyl)Ether SCHEMBL28680315 | 0.90 | PSMB8 (0.33) | PSMB8PSMB5EGLN1KDM6BKDM5C | |
| Ethylene Glycol SCHEMBL6129445 | 0.90 | TSHR (0.40) | PSMB8PSMB5LMNAKMT2AATM | |
| Methoxymethane SCHEMBL7956362 | 0.89 | EGLN1 (0.37) | PSMB8PSMB5EGLN1KDM6BKDM5C | |
| Ethylene Glycol SCHEMBL4908864 | 0.89 | PSMB8 (0.31) | PSMB8PSMB5KMT2A | |
| SCHEMBL2589620 | 0.88 | PSMB8 (0.34) | PSMB8PSMB5EGLN1KDM6BKDM5C | |
| Ethylene Glycol SCHEMBL28881509 | 0.88 | GPR84 (0.42) | PSMB8PSMB5LMNAKMT2ACAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114099784-A | Injection type skin filling composition and preparation method and application thereof | 四川兴科蓉药业有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| CN-118043084-A | Compositions and methods for metal-containing formulations capable of modulating immune responses | 密执安大学评议会 | 2024-05-14 | — | — | CN | disclosed |
| CN-118043068-A | RNA vaccine | 阿克丘勒斯治疗公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024094027-A1 | BLOCKING SEQUENCE, KIT THEREOF, AND METHOD FOR USING SAME | 深圳鸿生生物科技有限公司 | 2024-05-10 | — | — | WO | disclosed |
| CN-111432845-B | Method for protecting vascular integrity under targeted radiotherapy induction | 詹森药业有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117120076-A | Compositions and methods for treating hereditary angioedema | 斯帕克治疗公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116981770-A | Compositions and methods for treating brile disease | 斯帕克治疗公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116964207-A | Methods for enhancing nonviral gene therapy | 斯帕克治疗公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-114099784-B | Injection type skin filling composition and preparation method and application thereof | 四川兴科蓉药业有限责任公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114099784-A | Injection type skin filling composition and preparation method and application thereof | 四川兴科蓉药业有限责任公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20130018010-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | ENZON PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| CN-102869254-A | Polymeric conjugates of adenine nucleoside analogs | ENZON PHARMACEUTICALS INC | 2013-01-09 | — | — | CN | disclosed |
| CN-101082043-B | Polyethylene glycol modified L-asparaginyl amine enzyme | SHANGHAI INST PHARM INDUSTRY | 2012-10-10 | — | — | CN | disclosed |
| US-20110305770-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | ENZON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2011130599-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | ENZON PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| EP-2362728-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | Enzon Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010057150-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| CN-101082043-A | Polyethylene glycol modified L-asparaginyl amine enzyme | SHANGHAI INST PHARM INDUSTRY (CN) | 2007-12-05 | — | — | CN | disclosed |
| CN-1312279-C | Method for preparing elspar modilfied by carbowax | XINYANG MEDICINE CO LTD LIANYU (CN) | 2007-04-25 | — | — | CN | disclosed |
| CN-1498965-A | Method for preparing elspar modilfied by carbowax | 连云港新阳医药有限公司 | 2004-05-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305770-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | KPNA6, LPAR6, KAT6B | PSMB8 3216/4885PSMB5 3430/4885EGLN1 1785/4885 |
| US-20130018010-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | VEGFA, MKI67, PCNA | PSMB8 3490/4885PSMB5 3067/4885EGLN1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.